Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Sep 28, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Sep 14, 2026Reported sale · Form 4MATT ABERNETHY, Chief Financial Officer · $363.3KOpen the filing ↗
- Sep 14, 2026Reported sale · Form 4David W. Boyer, Chief Corp. Affairs Officer · $130.1KOpen the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record2,01815 flagged findings
Reported transactions (Form 4)80since May 15, 2026 · and 31 other holdings
Corporate events (8-K)30since May 30, 2018
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-05-18merger or acquisition eventrecentOpen filing ↗“…revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Introductory Note As previously…”
+1 more passage from the same document
- “…13(a) of the Exchange Act. ☐ Introductory Note As previously disclosed in the Current Report on Form 8-K filed with the…”
- 2026-05-05capital return (buybacks/dividends)recentOpen filing ↗“…shown in the condensed consolidated statements of cash flows. (in millions) March 31, 2026 March 31, 2025 Cash and cash…”
+1 more passage from the same document
- “…statements of cash flows. (in millions) March 31, 2026 March 31, 2025 Cash and cash equivalents $ 266.5 $ 194.1 Restricted cash…”
- 2026-05-05regulatory investigationrecentOpen filing ↗“…or actions pending against us is likely to have, individually or in the aggregate, a material adverse effect on our business,…”
+1 more passage from the same document
- “…program to help eligible patients afford our products. These and other types of programs have become the subject of…”
- 2026-05-05Department of Justice inquiryrecentOpen filing ↗“…to have, individually or in the aggregate, a material adverse effect on our business, financial condition, or results of…”
+1 more passage from the same document
- “…course of our business. We currently believe that none of the claims or actions pending against us is likely to have, individually…”
- 2026-05-05merger or acquisition eventrecentOpen filing ↗“…a civil investigative demand from the U.S. Department of Justice (DOJ) requesting certain documents and information related to…”
+1 more passage from the same document
- “…of 2026 increased $247.3 million, or 43.9%, to $811.0 million, reflecting increased net product sales of CRENESSITY, which was…”
- 2026-04-06merger or acquisition eventrecentOpen filing ↗“…of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has…”
+1 more passage from the same document
- “…not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 2,018)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Oct 15, 26SCHEDULE 13G/A ↗Passive stake · JPMORGAN CHASE & CO. · 5.2% · event on Sep 30, 26 · amendment new
- Oct 7, 26Form 3 ↗Insider transaction
- Sep 28, 268-K ↗Current report · A senior executive left or was appointed
Insider transaction · 10 Form 4 filingsshow all 10hide
- Sep 15, 26Form 4 ↗Insider transaction
- Sep 15, 26Form 4 ↗Insider transaction
- Sep 15, 26Form 4 ↗Insider transaction
- Sep 15, 26Form 4 ↗Insider transaction
- Sep 15, 26Form 4 ↗Insider transaction
- Sep 15, 26Form 4 ↗Insider transaction
- Sep 15, 26Form 4 ↗Insider transaction
- Sep 15, 26Form 4 ↗Insider transaction
- Sep 15, 26Form 4 ↗Insider transaction
- Sep 15, 26Form 4 ↗Insider transaction
Notice of proposed sale · 2 Form 144 filingsshow all 2hide
- Sep 14, 26Form 144 ↗Notice of proposed sale
- Sep 14, 26Form 144 ↗Notice of proposed sale
- Sep 10, 26Form 4 ↗Insider transaction
- Sep 9, 26Form 144 ↗Notice of proposed sale
- Jul 31, 268-K/A ↗Current report · Financial statements and exhibits · amendment
- Jul 31, 2610-Q ↗Quarterly report
- Jul 30, 26Form 4 ↗Insider transaction
- Jul 30, 268-K ↗Current report · Results
- Jul 27, 26SCHEDULE 13G/A ↗Passive stake · JPMORGAN CHASE & CO. · 6.3% · event on Jun 30, 26 · amendment
- Jul 13, 26Form 4 ↗Insider transaction
2,018 filings on record, the oldest from Jun 10, 96.
Listing the 25 most recent filings of the 2,018 on record.
55759
- Sep 28, 26A senior executive left or was appointed8-K 5.02 ↗
- May 28, 26A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- May 18, 26Entered a material agreement+4 more in the same filing8-K 1.01 ↗
- Apr 6, 26Entered a material agreement+1 more in the same filing8-K 1.01 ↗
4 senior executive changes2025show all 4hide
- Nov 24, 25A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- May 30, 25A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- May 22, 25A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Apr 4, 25A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jan 27, 25Entered a material agreement+2 more in the same filing8-K 1.01 ↗
6 senior executive changes2023 – 2024show all 6hide
- Oct 11, 24A senior executive left or was appointed8-K 5.02 ↗
- May 28, 24A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- May 23, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Jul 13, 23A senior executive left or was appointed8-K 5.02 ↗
- Jul 12, 23A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- May 19, 23A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Jan 9, 23Entered a material agreement8-K 1.01 ↗
- May 23, 22A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Nov 22, 21Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- Apr 16, 21A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Jun 16, 20Entered a material agreement+1 more in the same filing8-K 1.01 ↗
8 older filings not shown · The record reaches back to Oct 29, 04.
Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.
- May 5, 09Restructuring plan with committed costs+3 more in the same filing8-K 2.05 ↗
- Jan 14, 08Write-down of assets+2 more in the same filing8-K 2.06 ↗
- Dec 18, 07Restructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
- Aug 8, 06Restructuring plan with committed costs8-K 2.05 ↗
- Jul 26, 06Restructuring plan with committed costs8-K 2.05 ↗
The full record holds 5 stress filings.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- BlackRock, Inc.12.1%Mar 31, 25SCHEDULE 13G/A ↗
- The Vanguard Group10.2%Feb 28, 25SCHEDULE 13G/A ↗
- Dodge & Cox5.6%Mar 31, 25SCHEDULE 13G ↗
- Vanguard Capital Management5.2%Mar 31, 26SCHEDULE 13G ↗
- JPMORGAN CHASE & CO.5.2%Sep 30, 26SCHEDULE 13G/A ↗2 earlier filings
show one more holderhide
- STATE STREET CORPORATION4.8%Dec 31, 24SCHEDULE 13G ↗
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Sep 14, MATTHEW C ABERNETHY filed notice of intent to sell up to $361K. It is filed under a scheduled plan (10b5-1), arranged in advance.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
After the notice, they sold $363K on Sep 14, per their Form 4. That is 100% of the shares announced so far, and the window is still open.
View notice (Form 144) ↗+7 more recent notices · 7 with a later sale
- Sep 14, 26Sell$363KMATT ABERNETHYChief Financial Officer↗
- Sep 14, 26Sell$130KDavid W. BoyerChief Corp. Affairs Officer↗
- Sep 9, 26Sell$333KERIC BENEVICHChief Commercial Officer↗
- Jul 28, 26Sell$228KLeslie Norwalk V↗
- Jul 10, 26Sell$791KIngrid DelaetChief Regulatory Officer↗
- Jul 9, 26Sell$1.5MIngrid DelaetChief Regulatory Officer↗
- Jul 9, 26Sell$1.8MDarin LippoldtChief Legal Officer↗
- Jul 8, 26Sell$489KIngrid DelaetChief Regulatory Officer↗
- Jul 7, 26Sell$607KIngrid DelaetChief Regulatory Officer↗
Stock compensation, tax and giftsshow the 31 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Sep 11, 26Compensationamount n/aKEVIN CHARLES GORMAN↗
- Sep 11, 26Tax$1.2MKEVIN CHARLES GORMAN↗
- Sep 11, 26Compensationamount n/aDarin LippoldtChief Legal Officer↗
- Sep 11, 26Tax$378KDarin LippoldtChief Legal Officer↗
- Sep 11, 26Compensationamount n/aKyle GanoChief Executive Officer↗
- Sep 11, 26Tax$529KKyle GanoChief Executive Officer↗
- Sep 11, 26Compensationamount n/aKyle GanoChief Executive Officer↗
- Sep 11, 26Tax$155KKyle GanoChief Executive Officer↗
- Sep 11, 26Compensationamount n/aERIC BENEVICHChief Commercial Officer↗
- Sep 11, 26Tax$529KERIC BENEVICHChief Commercial Officer↗
- Sep 11, 26Compensationamount n/aMATT ABERNETHYChief Financial Officer↗
- Sep 11, 26Tax$423KMATT ABERNETHYChief Financial Officer↗
- Sep 11, 26Compensationamount n/aJulie CookeChief Human Resources Officer↗
- Sep 11, 26Tax$302KJulie CookeChief Human Resources Officer↗
- Sep 11, 26Compensationamount n/aSanjay Chandru KeswaniChief Medical Officer↗
- Sep 11, 26Tax$330KSanjay Chandru KeswaniChief Medical Officer↗
- Sep 11, 26Compensationamount n/aJude OnyiaChief Scientific Officer↗
- Sep 11, 26Tax$302KJude OnyiaChief Scientific Officer↗
- Sep 11, 26Compensationamount n/aDavid W. BoyerChief Corp. Affairs Officer↗
- Sep 11, 26Tax$302KDavid W. BoyerChief Corp. Affairs Officer↗
- Sep 11, 26Compensationamount n/aIngrid DelaetChief Regulatory Officer↗
- Sep 11, 26Tax$378KIngrid DelaetChief Regulatory Officer↗
- Sep 9, 26Compensation$138KERIC BENEVICHChief Commercial Officer↗
- Sep 2, 26Giftamount n/aSTEPHEN A SHERWIN↗
- Aug 4, 26Giftamount n/aJude OnyiaChief Scientific Officer↗
- Jul 29, 26Compensation$117KLeslie Norwalk V↗
- Jul 10, 26Compensation$463KIngrid DelaetChief Regulatory Officer↗
- Jul 9, 26Compensation$873KIngrid DelaetChief Regulatory Officer↗
- Jul 9, 26Compensation$815KDarin LippoldtChief Legal Officer↗
- Jul 8, 26Compensation$283KIngrid DelaetChief Regulatory Officer↗
- Jul 7, 26Compensation$352KIngrid DelaetChief Regulatory Officer↗
The full record holds 598 transactions and goes back to Jun 1, 18.
Its sector and its market
Neurocrine Biosciences Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Neurocrine Biosciences Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Neurocrine Biosciences Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 2,018 documents on file, from Jun 10, 1996 to Oct 15, 2026.
- Company description
- Wikipedia, read on Sep 3, 2026.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.